Effect of preoperative atorvastatin therapy on paraoxonase activity and oxidative stress after coronary artery bypass grafting.
The aim of this study was to examine the influence of preoperative atorvastatin therapy on oxidative stress in coronary artery bypass grafting (CABG) patients. Forty patients who underwent elective CABG were enrolled into the study. Of these patients, 20 received atorvastatin (Group I) for 15 days prior to surgery and 20 patients did not use any antihyperlipidemic agents preoperatively (Group II). Serum paraoxonase 1 (PON1) and arylesterase activities, and total antioxidant status (TAS) and total oxidant status (TOS) were measured before surgery and at 1, 6 and 24 hours after the operation. Paraoxonase 1 and arylesterase activities (p<0.001) and TAS levels (p<0.001 for 1(st) hour and p<0.05 for 6(th) hour) in Group II were significantly reduced at the 1( st) and 6(th) hours after the operation, whereas the activities of the enzymes (p<0.01) and TAS levels (p<0.05) were significantly reduced only at the 1(st) hour after the operation in Group I. The total oxidant status of both groups was significantly increased at the 1( st) hour after operation (p<0.05 for Group I and p<0.01 for Group II). In conclusion, 15 days of preoperative atorvastatin therapy does not significantly change either the serum PON1 activity or the oxidative stress after CABG.
Department of Biochemistry, Meram Faculty of Medicine, University of Selcuk, 42080, Konya, Turkey. svlkrbn@yahoo.com
Sevil
S
Kurban
Idris
I
Mehmetoglu
Erdal
E
Ege
D000368:Aged; D000975:Antioxidants / Q000008:administration & dosage / Q000627:therapeutic use*; D043303:Aryldialkylphosphatase / Q000097:blood*; D000069059:Atorvastatin; D002265:Carboxylic Ester Hydrolases / Q000097:blood; D001026:Coronary Artery Bypass / Q000009:adverse effects*; D003327:Coronary Disease / Q000097:blood / Q000201:enzymology* / Q000601:surgery; D005260:Female; D006538:Heptanoic Acids / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D016877:Oxidants / Q000097:blood; D018384:Oxidative Stress / Q000187:drug effects*; D011300:Preoperative Care; D011758:Pyrroles / Q000008:administration & dosage / Q000627:therapeutic use*
D000975:Antioxidants; D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D016877:Oxidants; D011758:Pyrroles; D000069059:Atorvastatin; D002265:Carboxylic Ester Hydrolases; C019734:arylesterase; D043303:Aryldialkylphosphatase